


Claims:

1. (Original) A method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a compound which is an EP₄ agonist.
2. (Original) The method of claim 1 wherein said compound is represented by the general formula I;




wherein hatched lines represent the α configuration, a triangle represents the β configuration, a wavy line represents either the α configuration or the β configuration and a dotted line represents the presence or absence of a double bond;

A and B are independently selected from the group consisting of O, S and CH₂, provided that at least one of A or B is S;

D represents a covalent bond or CH₂, O, S or NH;

X is CO₂R, CONR₂, CH₂OR, P(O)(OR)₂, CONRSO₂R, SONR₂ or



Y is O, OH, OCOR², halogen or cyano;

Z is CH₂ or a covalent bond;


R is H or R²;

R¹ is H, R², phenyl, or COR²;


R² is C₁-C₅ lower alkyl or alkenyl;

R₃ is benzothienyl, benzofuranyl, naphthyl, or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C₁-C₅ alkyl, halogen, CF₃, CN, NO₂, NR₂, CO₂R and OR and R⁴ is hydrogen or C₁-C₅ lower alkyl.

3. (Original) The method according to claim 2 wherein said compound is represented by the general formula II;



4. (Original) The method according to claim 3 wherein said compound is represented by the general formula III;



5. (Original) The method of claim 2 wherein Z represents a covalent bond.
6. (Original) The method of claim 2 wherein D represents a covalent bond or is CH₂.
7. (Original) The method of claim 2 wherein X is CO₂ R.
8. (Original) The method of claim 7 wherein R is selected from the group consisting of H, methyl, i-propyl, and n-propenyl.
9. (Original) The method of claim 2 wherein R is H, or n-propenyl.

10. (Original) The method of claim 2 wherein R_1 is H.
11. (Original) The method of claim 2 wherein D is CH_2 .
12. (Original) The method of claim 11 wherein R^3 is benzo[b]thienyl, 3-chlorobenzo[b]thienyl or naphthyl.
13. (Cancelled) An ophthalmic solution comprising a therapeutically effective amount of a compound which is EP_4 agonist.
14. (Cancelled) A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic solution according to claim 13 in said container.
15. (Original) The method of claim 1 wherein said compound is GR 50209X.